



# NCI Legislative Update

## Clinical Trials and Translational Research Advisory Committee

November 30, 2012

Susan Erickson

Director, Office of Government and  
Congressional Relations

# Discussion Topics

Congressional Priorities

Legislation of Interest



# Congressional Priorities

## Lame Duck Session (Nov – Dec 2012)

➤ Caucus Organization



➤ Threat of Sequestration



# Congressional Priorities

New Congress Convenes January, 2013

Committee Appointments for new members



Threat of Sequestration



FY 2013 Appropriations



# Appropriations Status – FY 2013

## Where are we?

- Government is operating under a Continuing Resolution (CR) that expires March 27, 2013

## What's Next?

- Omnibus bill

OR

- Full year CR



# Discussion Topics

Congressional Priorities

Legislation of Interest





# Recalcitrant Cancer Research Act

HR 733/S 362

- Originally introduced as **Pancreatic Cancer Research Act in February 2011**
- House Sponsors – Eshoo (D-CA); Lance (R-NJ)  
Senate Sponsor – Whitehouse (RI)
- Bipartisan support – many co-sponsors
  - House = 294; Senate = 58



# Pancreatic Cancer Research Act

## Key Provisions

- NCI establish Pancreatic Cancer Initiative
- HHS establish Interdisciplinary Pancreatic Cancer Coordinating Committee (with authority to make recommendations on prioritization and award of grants)
- Membership of committee to include: 11 pancreatic cancer research experts who have received NIH grants; NCI Director; 1 pancreatic cancer advocate
- Authorize appropriations for pancreatic cancer research totaling \$169 Million





# How the Pancreatic Cancer Research Act Became the Recalcitrant Cancer Research Act

## House Action – September 2012

- HR 733 amended - replaced text and changed title
- Passed House on Sept. 19

## Senate Action – 2012

- S 3566, which included the new text of HR 733 was introduced by Sen. Harkin on Sept. 20
- To date, Senate has not voted on bill



# Recalcitrant Cancer Research Act

## Key Provisions

- NCI develop scientific framework to conduct and support research for recalcitrant cancers
- Criteria: 5-year survival  $< 20\%$  and mortality must be  $> 30,000$  per year
- NCI convene working group to provide expertise, assistance in developing framework
- Frameworks must be submitted to Congress and made publicly available



NATIONAL<sup>®</sup>  
CANCER  
INSTITUTE

---